Global Prostate Health Market Insights Forecasts to 2033

• The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023
• The Market Size is Growing at a CAGR of 9.12% from 2023 to 2033
• The Worldwide Prostate Health Market Size is Expected to Reach USD 78.03 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Prostate Health Market Size is Anticipated to Exceed USD 78.03 Billion by 2033, Growing at a CAGR of 9.12% from 2023 to 2033.

 

Market Overview

Prostate cancer is the term for cancer that develops in the prostate. The seminal fluid, which feeds and carries sperm, is produced by the prostate, a little gland in men that resembles a walnut in shape. It impacts a greater percentage of older males, making it a major health concern, particularly in developed nations. Many prostate tumors only appear in the prostate gland, grow slowly, and may not cause any symptoms. Others would require therapy, while others might spread quickly and result in serious harm. Exercise can help cancer patients in many ways, such as enhancing their quality of life and enabling them to do daily duties. Prostate cancer is a slow-growing disease that first affects only the prostate gland but can also spread to other body parts, particularly the lymph nodes and bones. Longer survival rates and a decreased rate of progression after a prostate cancer diagnosis have also been linked to physical activity. The worldwide market for prostate cancer treatments provides significant market insights in addition to a dynamic environment. The market expansion was driven by prostate cancer, which is one of the most frequent malignancies in males worldwide. Providing patients with prostate cancer with innovative and efficient therapy is the main goal of the worldwide market for prostate cancer treatments. The market's revenue growth is attributed to factors such as smoking, obesity rates, lifestyle issues, and the development of advanced procedures for diagnosing and treating prostate cancer. The rising prevalence of benign prostatic hyperplasia, rising obesity rates, investments, funds, and grants for research into BPH treatment, the rising incidence of prostatitis, the rising demand for hormone therapy drugs, the developing therapies for prostate cancer, and the rising prevalence of prostate cancer are the main factors driving the market's growth.       

 

Report Coverage

This research report categorizes the market for the global prostate health market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global prostate health market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global prostate health market.

 

Driving Factors

The market is anticipated to develop at a rapid pace due to factors such as the increasing focus on patient-centre care and customized medicine, the expansion of cancer institutes and centers the world wide and an increase in the number of clinical trials for prostate cancer therapies. During the projection period, the market expansion is also being driven by the availability of long-acting high-incidence products and the increasing prevalence of target diseases. The market is growing owing to technological advancements in imaging methods, robotic-assisted surgery, and precision medicine, among other treatment modalities. Overall patient outcomes are improved by these technologies, which also improve early detection, accurate diagnosis, and customized treatment plans. Since prostate cancer incidence rises with age, the aging of the world's population supports the expansion of the prostate cancer market.

 

Restraining Factors

Prostate cancer can spread to bones and other organs, including the bladder, via the lymphatic or circulatory systems. Prostate cancer and its treatment can both result in urinary incontinence. Erectile dysfunction may result from prostate cancer and its treatments, including hormone therapy, radiation, and surgery. The market expansion is also being impeded by the high cost of cancer treatment and the low success rate of clinical trials for oncology treatments. 

 

Market Segmentation

The global prostate health market share is classified into disease indication, distribution channel, and treatment.

The prostate cancer segment accounted for the largest revenue share through the forecast period.

Based on the disease indication, the global prostate health market is categorized into benign prostate hyperplasia (BPH), prostate cancer, alpha-blockers, prostatitis, and others. Among these, the prostate cancer segment accounted for the largest revenue share through the forecast period. Prostate cancer is a condition where the tissues of the prostate develop malignant (cancer) cells. Government support for research and the presence of a robust pipeline are credited with this increase. The quick development of technology in the field of cancer and a notable rise in R&D spending by both the public and commercial sectors are further factors contributing to the market expansion of this segment.

 

• The hormone ADT is anticipated to grow at the fastest CAGR growth through the forecast period.

Based on the treatment, the global prostate health market is categorized into radiation therapy, hormone ADT, AR-directed therapies, cytotoxic agents, therapeutics, and others. Among these, the hormone ADT is anticipated to grow at the fastest CAGR growth through the forecast period. The increasing need for prostate cancer treatment items is responsible for this growth. Androgens, a hormone associated with male sex, feed prostate cancer and can potentially delay the disease's spread. The first line of treatment for symptomatic metastatic prostate cancer is generally agreed to be ADT.

 

• The e-commerce segment is predicted to dominate the global prostate health market during the forecast period.

Based on the distribution channel, the global prostate health market is categorized into e-commerce stores, pharmacies, and others. Among these, the e-commerce segment is predicted to dominate the global prostate health market during the forecast period. Due to their convenience and rapid growth, traditional drugstores are being replaced by online pharmacies. Prescription medication can be easily and conveniently purchased online by older persons and those who live distant from physical pharmacies. E-commerce sites also save time and money. It is feasible to simply acquire prescription drugs online.

 

Regional Segment Analysis of the Global Prostate Health Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global prostate health market over the predicted timeframe.

 

Get more details on this report -

Request Free Sample PDF

 

North America is anticipated to hold the largest share of the global prostate health market over the predicted timeframe. Due to owing improvements in treatment and the increasing incidence of benign prostate hyperplasia (BPH). Prostate health industry growth in the region has also been facilitated by favorable compensation rules, research funding, a strong healthcare infrastructure, and a rise in new product debuts. The rising target population, the high prevalence of benign prostate hyperplasia (BPH), prostate cancer, and prostatitis, and the dominance of medical device makers are all factors contributing to the expansion of the North American market.

 

Asia Pacific is expected to grow at the fastest CAGR growth of the global prostate health market during the forecast period. An aging population, rising physician awareness, and rising healthcare spending are all expected to increase the need for prostate health treatments in the Asia Pacific region. Increased prostate-specific antigen (PSA) screening adoption in these areas is blamed for the increase in incidence.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global prostate health market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• AbbVie, Inc.
• Pfizer, Inc.
• Bayer AG
• Lily
• AbbVie Inc.
• Ferring Pharmaceuticals Inc.
• Nucleai, Inc.
• Clovis Oncology, Inc.
• Eli Lilly and Company
• Astellas Pharma Inc.
• Johnson & Johnson
• Abbott Laboratories
• Gilead Sciences, Inc
• Teva Pharmaceutical Industries Ltd
• Amgen, Inc.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In September 2023, MDxHealth SA and the University of Oxford worked together. The partnership seeks to investigate the relationship between the Genomic Prostate Score (GPS) test and the advancement of prostate cancer following localized prostate cancer treatment.

 

• In January 2021, The Pfizer-Myovant firm cooperation was announced in order to launch the medication Orgovyx (relugolix).

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global prostate health market based on the below-mentioned segments: 

 

Global Prostate Health Market, By Disease Indication

• Benign Prostate Hyperplasia (BPH)
• Prostate Cancer
• Alpha Blockers
• Prostatitis
• Others

 

Global Prostate Health Market, By Treatment

• Radiation Therapy
• Hormone ADT
• AR Directed Therapies
• Cytotoxic Agents and Therapeutics
• Others

 

Global Prostate Health Market, By Distribution Channel

• E-Commerce Stores
• Pharmacies 
• Others

 

Global Prostate Health Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa